ANALYSIS OF THE CLASSIFICATION OF HERPES ZOSTER VIRUS AND PRINCIPLES FOR IMPROVING LABORATORY DIAGNOSTICS

Authors

  • Karima Rashiddinovna Abdurakhmonova, Ilkhomova Munisa Zafar kizi , Ko’palova Mekhrangiz Muzaffar kizi , Shakhzoda Odiljonovna Olimova Assistant of the Department of Microbiology, Virology, and Immunology at TSMU,1- Student of the Faculty of Medicine at TSMU,1- Student of the Faculty of Medicine at TSMU,1- Student of the Faculty of Medicine at TSMU Author

DOI:

https://doi.org/10.5281/zenodo.20516365

Keywords:

CNS, varicella zoster virus, herpes viruses, HSV-1, HSV-2, VZV, herpes zoster, post-herpetic neuralgia

Abstract

A serious health concern that can impact people of any age is herpes zoster. People over 50, those with impaired immune systems, and those using immunosuppressive medications are more likely to experience it. The varicella zoster virus reactivation is the cause. This reactivation is influenced by cell-mediated immunity. Before a rash appears, frequent symptoms include fever, discomfort, and itching. The most frequent side effect of herpes zoster is post-herpetic neuralgia. Age, immunological state, and the timing of therapy initiation all affect risk factors and problems related to herpes zoster. Herpesvirus-induced infections of the central nervous system (CNS) have different epidemiologies depending on host characteristics and geographic distribution. Early diagnosis and treatment can save lives. This study assessed an internal laboratory methodology for cerebrospinal fluid (CSF) molecular testing criteria, examined the epidemiology of herpesvirus CNS infections in Western Greece, and compared clinical and laboratory results with global data. 940 out of 4300 CSF samples were eligible for RT-PCR detection of varicella zoster virus (VZV) and herpes simplex virus (HSV-1, HSV-2) during the research period. 53 (5.63%) of them tested positive: 7 HSV-2, 9 HSV-1, and 37 VZV. The greatest CSF white blood cell (WBC) counts (231/mm3) were seen in HSV-2 cases, which were found in younger patients (median age 41), followed by VZV (125/mm3) and HSV-1 (26/mm3). HSV-2 infections had greater levels of CSF protein. The most sensitive imaging technique for identifying CNS inflammation was magnetic resonance imaging (MRI). These findings show that VZV is the most common herpesvirus in this area, highlighting the importance of prompt molecular identification and high clinical suspicion in elderly patients.

References

1.Kakouris V, Kalyva N, Militsopoulou M, Stamouli V, Meletis G, Kachrimanidou M, Paliogianni F. Epidemiology of Herpes Simplex and Varicella Zoster Virus-Associated Central Nervous System Infections in Western Greece: A Five-Year Retrospective Analysis. Pathogens. 2026; 15(1):30. https://doi.org/10.3390/pathogens15010030

2.Kadambari, S.; Abdullahi, F.; Celma, C.; Ladhani, S. Epidemiological trends in viral meningitis in England: Prospective national surveillance, 2013–2023. J. Infect. 2024, 89, 106223.

3.Parkes-Smith, J.; Chaudhuri, A. Varicella Zoster Virus: An under-recognised cause of central nervous system infections? Intern. Med. J. 2020, 52, 100–104.

4.Pormohammad, A.; Goudarzi, H.; Eslami, G.; Falah, F.; Taheri, F.; Ghadiri, N.; Faghihloo, E. Epidemiology of Herpes simplex and Varicella zoster virus in Cerebrospinal fluid of patients suffering from meningitis in Iran. New Microbes New Infect. 2020, 30, 100688.

5.Lal H, Cunningham AL, Godeaux O, Chlibek R, Diez-Domingo J, Hwang SJ, et al. Efficacy of an adjuvanted herpes zoster subunit vaccine in older adults. N Engl J Med 2015;372:2087-96.

6.Ansaldi F, Trucchi C, Alicino C, Paganino C, Orsi A, Icardi G, et al. Real-world effectiveness and safety of a live-attenuated herpes zoster vaccine: A Comprehensive review. Adv Ther 2016;33:1094-104.

7.Gabutti G, Franco E, Bonanni P, Conversano M, Ferro A, Lazzari M, et al. Reducing the burden of herpes zoster in italy. Hum Vaccin Immunother 2015;11:101-7.

8.Diez-Domingo J, Weinke T, Garcia de Lomas J, Meyer CU, Bertrand I, Eymin C, et al. Comparison of intramuscular and subcutaneous administration of a herpes zoster live-attenuated vaccine in adults aged ≥50 years: A randomised non-inferiority clinical trial. Vaccine 2015;33:789-95.

9.Jeon YH. Herpes zoster and postherpetic neuralgia: Practical consideration for prevention and treatment. Korean J Pain 2015;28:177-84.

10.Johnson BH, Palmer L, Gatwood J, Lenhart G, Kawai K, Acosta CJ, et al. Annual incidence rates of herpes zoster among an immunocompetent population in the united states. BMC Infect Dis 2015;15:502.

11.Garber, B.; Glauser, J. Viral Meningitis and Encephalitis Update. Curr. Emerg. Hosp. Med. Rep. 2024, 12, 95–102. Aldriweesh, M.A.; Shafaay, E.A.; Alwatban, S.M.; Alkethami, O.M.; Aljuraisi, F.N.; Bosaeed, M.; Alharbi, N.K. Viruses Causing Aseptic Meningitis: A Tertiary Medical Center Experience with a Multiplex PCR Assay. Front. Neurol. 2020, 11, 602267

12.Matthews, E.; Beckham, J.D.; Piquet, A.L.; Tyler, K.L.; Chauhan, L.; Pastula, D.M. Herpesvirus-Associated Encephalitis: An Update. Curr. Trop. Med. Rep. 2022, 9, 92–100.

13.Albert, E.; Alberola, J.; Bosque, M.; Camarena, J.J.; Clari, M.Á.; Márquez, M.V.D.; Gil-Fortuño, M.; Gimeno, A.; Nogueira, J.M.; Ocete, M.D.; et al. Missing Cases of Herpes Simplex Virus (HSV) Infection of the Central Nervous System When the Reller Criteria Are Applied for HSV PCR Testing: A Multicenter Study. J. Clin. Microbiol. 2019, 57, e01719-18.

14.Lee, G.-H.; Kim, J.; Kim, H.-W.; Cho, J.W. Herpes simplex viruses (1 and 2) and varicella-zoster virus infections in an adult population with aseptic meningitis or encephalitis. Medicine 2021, 100, e27856.

15.Ishimaru, S.; Kawamura, Y.; Miura, H.; Shima, S.; Ueda, A.; Watanabe, H.; Mutoh, T.; Yoshikawa, T. Detection of human herpesviruses in cerebrospinal fluids collected from patients suspected of neuroinfectious diseases. J. NeuroVirol. 2021, 28, 92–98.

16.Ma, C.; Lu, Y.; Zhang, Q.; Chen, H.; Zhang, Q.; Hu, H.; Song, Z.; Chen, R.; Liu, D. Comparisons in the changes of clinical characteristics and cerebrospinal fluid cytokine profiles between varicella-zoster virus meningitis/encephalitis and other central nervous system infections. Zhong Nan Da Xue Xue Bao Yi Xue Ban = J. Cent. South Univ. Med. Sci. 2022, 47, 1345–1354.

17.Shikova, E.; Kumanova, A.; Tournev, I.; Zhelyazkova, S.; Vassileva, E.; Ivanov, I.; Pishmisheva, M. Varicella zoster virus infection in neurological patients in Bulgaria. J. NeuroVirol. 2021, 27, 272–278.

18.Rohani, H.; Arjmand, R.; Mozhgani, S.-H.; Shafiee, A.; Amini, M.J.; Forghani-Ramandi, M.-M. The Worldwide Prevalence of Herpes Simplex Virus Encephalitis and Meningitis: A Systematic Review and Meta-Analysis. Turk. Arch. Pediatr. 2023, 58, 580–587.

19.Tabaja, H.; Sharara, S.; Aad, Y.A.; Beydoun, N.; Tabbal, S.; Makki, A.; Mahfouz, R.; Kanj, S. Varicella zoster virus infection of the central nervous system in a tertiary care center in Lebanon. Méd. Mal. Infect. 2020, 50, 280–287.

20.L. Antoniolli, C. Rodrigues, R. Borges, L.Z. Goldani. Epidemiology and clinical characteristics of herpes zoster in a tertiary care hospital in Brazil. Braz J Infect Dis, 23 (2019), pp. 143-145 http://dx.doi.org/10.1016/j.bjid.2019.03.001

21.H.A. Shah, A. Meiwald, C. Perera, G. Casabona, P. Richmond, N. Jamet. Global prevalence of varicella-associated complications: a systematic review and meta-analysis. Infect Dis Ther, 13 (2024), pp. 79-103 http://dx.doi.org/10.1007/s40121-023-00899-7

22.C.X. Pan, M.S. Lee, V.E. Nambudiri. Global herpes zoster incidence, burden of disease, and vaccine availability: a narrative review. Ther Adv Vaccines Immunother, 10 (2022), pp. 1-19 I.

23.Williame, M. George, H.A. Shah, N. Homer, D. Alderson, N. Jamet. Healthcare resource use and costs of varicella and its complications: a systematic literature review. Hum Vaccin Immunother, 19 (2023),

Downloads

Published

2026-06-03